secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001213900-26-048277
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics receives USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent
--------------------------------------------------------------------------------

- Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
- Patent expected to be granted within three months; would provide exclusivity at least into 2039 for stenoparib with DRP test.
- Allarity previously secured European and Australian patents for Stenoparib DRP; holds 18 granted patents for other drug-specific DRPs.
- Patent applications for Stenoparib DRP remain pending in Canada, Japan, China, and India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026048277/0001213900-26-048277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026048277/ea0287908-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-048277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer